Wei Tang1, Xian Li2, Zhen-Zhuo Ma3, Chun-Ying Li4. 1. Department of Blood Transfusion, The Affiliated Hospital of BeiHua University, Jilin 132011, Jilin Province, China. 2. Department of Hematology and Poisoning, Jilin 132011, Jilin Province, China. E-mail: lixianjhzyy@126.com. 3. Department of Radiology, The General Hospital of Jilin Chemical Industry Group, Jilin 132011, Jilin Province, China. 4. Department of Hematology and Poisoning, Jilin 132011, Jilin Province, China.
Abstract
OBJECTIVE: To investigate the expression of retinol-binding protein (RBP) in patients with acute myeloid leukemia (AML) and its related factors. METHODS: The clinical data of 123 patients with AML from October 2012 to February 2016 and 100 healthy controls were collected and the correlation of RBP expression level with sex, French-American-British (FAB) subtypes, molecular mutations, peripheral white blood cells and long-term outcomes was analyzed. RESULTS: Compared with AML patients, the RBP expression level was significantly higher in healthy controls (61.02±34.97 vs 34.44±14.08 mg/L)(u=8.658, P<0.01). Patients with M3 showed higher RBP level (40.74±15.79 mg/L) compared with that of M4 (28.40±13.64 mg/L)(P<0.01) and M5 (31.97±15.31 mg/L)(P<0.05). Negative correlation was observed for RBP and white blood cells in patients with AML (r=-0.352, P<0.001), which was more remarkable in patients with M4 (r=-0.563, P<0.01) and M5 (r=-0.423, P<0.01). AML patients achieved complete remission (CR) (48.64±9.24 mg/L) showed higher RBP level than that before treatment (u=4.876, P<0.01), but lower than healthy controls (u=2.106,P<0.05). After CR, patients with M3 showed higher RBP level than that of non-M3 patients (54.91±5.25 mg/L vs 41.36±7.33 mg/L)(t=8.777,P<0.01). CONCLUSION: Detecting RBP expression may provide some useful information for urderstanding the pathophysiology and improving the treatment of patients with AML.
OBJECTIVE: To investigate the expression of retinol-binding protein (RBP) in patients with acute myeloid leukemia (AML) and its related factors. METHODS: The clinical data of 123 patients with AML from October 2012 to February 2016 and 100 healthy controls were collected and the correlation of RBP expression level with sex, French-American-British (FAB) subtypes, molecular mutations, peripheral white blood cells and long-term outcomes was analyzed. RESULTS: Compared with AMLpatients, the RBP expression level was significantly higher in healthy controls (61.02±34.97 vs 34.44±14.08 mg/L)(u=8.658, P<0.01). Patients with M3 showed higher RBP level (40.74±15.79 mg/L) compared with that of M4 (28.40±13.64 mg/L)(P<0.01) and M5 (31.97±15.31 mg/L)(P<0.05). Negative correlation was observed for RBP and white blood cells in patients with AML (r=-0.352, P<0.001), which was more remarkable in patients with M4 (r=-0.563, P<0.01) and M5 (r=-0.423, P<0.01). AMLpatients achieved complete remission (CR) (48.64±9.24 mg/L) showed higher RBP level than that before treatment (u=4.876, P<0.01), but lower than healthy controls (u=2.106,P<0.05). After CR, patients with M3 showed higher RBP level than that of non-M3 patients (54.91±5.25 mg/L vs 41.36±7.33 mg/L)(t=8.777,P<0.01). CONCLUSION: Detecting RBP expression may provide some useful information for urderstanding the pathophysiology and improving the treatment of patients with AML.